1
|
Kori M, Temiz K, Gov E. Network medicine approaches for identification of novel prognostic systems biomarkers and drug candidates for papillary thyroid carcinoma. J Cell Mol Med 2023; 27:4171-4180. [PMID: 37859510 PMCID: PMC10746936 DOI: 10.1111/jcmm.18002] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2023] [Revised: 09/21/2023] [Accepted: 10/07/2023] [Indexed: 10/21/2023] Open
Abstract
Papillary thyroid carcinoma (PTC) is one of the most common endocrine carcinomas worldwide and the aetiology of this cancer is still not well understood. Therefore, it remains important to understand the disease mechanism and find prognostic biomarkers and/or drug candidates for PTC. Compared with approaches based on single-gene assessment, network medicine analysis offers great promise to address this need. Accordingly, in the present study, we performed differential co-expressed network analysis using five transcriptome datasets in patients with PTC and healthy controls. Following meta-analysis of the transcriptome datasets, we uncovered common differentially expressed genes (DEGs) for PTC and, using these genes as proxies, found a highly clustered differentially expressed co-expressed module: a 'PTC-module'. Using independent data, we demonstrated the high prognostic capacity of the PTC-module and designated this module as a prognostic systems biomarker. In addition, using the nodes of the PTC-module, we performed drug repurposing and text mining analyzes to identify novel drug candidates for the disease. We performed molecular docking simulations, and identified: 4-demethoxydaunorubicin hydrochloride, AS605240, BRD-A60245366, ER 27319 maleate, sinensetin, and TWS119 as novel drug candidates whose efficacy was also confirmed by in silico analyzes. Consequently, we have highlighted here the need for differential co-expression analysis to gain a systems-level understanding of a complex disease, and we provide candidate prognostic systems biomarker and novel drugs for PTC.
Collapse
Affiliation(s)
- Medi Kori
- Faculty of Health SciencesAcibadem Mehmet Ali Aydinlar UniversityİstanbulTürkiye
- Department of BioengineeringMarmara UniversityİstanbulTürkiye
| | - Kubra Temiz
- Department of BioengineeringAdana Alparslan Turkes Science and Technology UniversityAdanaTürkiye
| | - Esra Gov
- Department of BioengineeringAdana Alparslan Turkes Science and Technology UniversityAdanaTürkiye
| |
Collapse
|
2
|
He T, Xia H, Chen B, Duan Z, Huang C. m6A Writer METTL3-Mediated lncRNA LINC01125 Prevents the Malignancy of Papillary Thyroid Cancer. Crit Rev Immunol 2023; 43:43-53. [PMID: 37824376 DOI: 10.1615/critrevimmunol.2023050267] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2023]
Abstract
BACKGROUND Long non-coding RNA (lncRNA) LINC01125 is an anti-tumor factor in a variety of tumors, and regulates cancer cell function. However, its function and mechanism of N6-methyladenosine (m6A) modification in papillary thyroid cancer (PTC) tumorigenesis remain unclear. AIMS This study aimed to reveal the function and m6A modification of LINC01125 in PTC tumorigenesis. METHODS The LINC01125 and methyltransferase-like 3 (METTL3) levels in PTC cells and tissues was assessed by qRT-PCR. The binding relationship among LINC01125 and METTL3 was determined by MeRIP, Pearson, bioinformatics, and RNA stabilization analysis. Transwell assays were performed to confirm the changes of PTC cell migration and invasion. Cell proliferation was revealed by CCK-8 as well as colony formation assays. RESULTS Low expression of LINC01125 and METTL3 was identified in PTC. LINC01125 was a downstream target of METTL3-mediated m6A modification and was stably upregulated via METTL3. Cell invasion, migration, viability, and colony formation levels were decreased when LINC01125 or METTL3 was upregulated. Inhibition of LINC01125 had the opposite impact, promoting cell proliferation and metastasis, and reversing METTL3 overexpression-resulted cell malignancy suppression. CONCLUSIONS Overall, this study proved that the m6A modification of LINC01125 was mediated by METTL3 and LINC01125 inhibited cell invasion, migration and proliferation, thereby suppressing the development of PTC. This points to the LINC01125-m6A-METTL3 axis as a possible prospective target for future treatment of PTC.
Collapse
Affiliation(s)
- Tianyou He
- Department of General Surgery, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan 430060, Hubei, China
| | - Hailiang Xia
- Department of General Surgery, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan 430060, Hubei, China
| | - Baojie Chen
- Department of General Surgery, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan 430060, Hubei, China
| | - Ziqi Duan
- Department of General, Jianghan University, Wuhan 430056, Hubei, China
| | - Chaogang Huang
- Department of General Surgery, Wuhan Third Hospital (Tongren Hospital of Wuhan University), Wuhan 430060, Hubei, China
| |
Collapse
|
3
|
Lopes NMD, Lens HHM, da Silva Brito WA, Bianchi JK, Marinello PC, Cecchini R, Armani A, Cecchini AL. Role of papillary thyroid carcinoma patients with Hashimoto thyroiditis: evaluation of oxidative stress and inflammatory markers. CLINICAL & TRANSLATIONAL ONCOLOGY : OFFICIAL PUBLICATION OF THE FEDERATION OF SPANISH ONCOLOGY SOCIETIES AND OF THE NATIONAL CANCER INSTITUTE OF MEXICO 2022; 24:2366-2378. [PMID: 35902455 DOI: 10.1007/s12094-022-02891-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/11/2022] [Accepted: 07/12/2022] [Indexed: 11/30/2022]
Abstract
PURPOSE Papillary thyroid carcinoma (PTC) is the most frequent subtype of thyroid cancer; Hashimoto's thyroiditis (HT), autoimmune disease, commonly affects the thyroid gland; there is possibly a correlation between both, but the exact mechanisms that involve this relationship are still under debate. Since oxidative stress (OS) and the inflammatory environment participate in the development of several types of cancer, the objective of the present study was to establish the microenvironment and systemic participation of OS and inflammatory markers in patients with PTC and HT. METHODS Blood and tissue samples were collected from 115 patients: BENIGN (n = 63); PTC (n = 27); HT (n = 15) and PTC + HT (n = 10), and sixty-three were samples from healthy individuals (control group). RESULTS Superoxide dismutase, Catalase, reduced Glutathione, markers of lipid peroxidation and inflammation were evaluated in blood. Immunohistochemistry was performed on 3-nitrotyrosine, 4-hydroxynonenal, Ki-67 and VEGF. The results indicate that antioxidant enzymes were more active in groups with thyroid disorders compared to control, while the concentration of Reduced glutathione was reduced in BENIGN and PTC groups. When PTC and PTC + HT groups were analyzed, no significant differences were found in relation to the antioxidant defense and inflammatory markers. The ability to contain the induced lipid peroxidation was lower and a high level of malondialdehyde was observed in the PTC group. All immunohistochemical markers had higher scores in the PTC group compared to PTC + HT. CONCLUSION There was a more pronounced presence of OS and a greater activity of cell proliferation and angiogenesis markers in PTC than in PTC + HT group.
Collapse
Affiliation(s)
- Natália Medeiros Dias Lopes
- Laboratory of Molecular Pathology, Universidade Estadual de Londrina, Celso Garcia Cid, PR445, Km 380 University Campus, Londrina, Paraná, CEP 86057-970, Brazil
| | - Hannah Hamada Mendonça Lens
- Laboratory of Molecular Pathology, Universidade Estadual de Londrina, Celso Garcia Cid, PR445, Km 380 University Campus, Londrina, Paraná, CEP 86057-970, Brazil
| | - Walison Augusto da Silva Brito
- Laboratory of Molecular Pathology, Universidade Estadual de Londrina, Celso Garcia Cid, PR445, Km 380 University Campus, Londrina, Paraná, CEP 86057-970, Brazil.,Leibniz-Institute for Plasma Science and Technology (INP Greifswald), ZIK Plasmatis "Plasma Redox Effects", Greifswald, Germany
| | - Julya Karen Bianchi
- Laboratory of Molecular Pathology, Universidade Estadual de Londrina, Celso Garcia Cid, PR445, Km 380 University Campus, Londrina, Paraná, CEP 86057-970, Brazil
| | - Poliana Camila Marinello
- Laboratory of Molecular Pathology, Universidade Estadual de Londrina, Celso Garcia Cid, PR445, Km 380 University Campus, Londrina, Paraná, CEP 86057-970, Brazil.,Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Rubens Cecchini
- Laboratory of Physiopathology and Free Radicals, Universidade Estadual de Londrina, Londrina, PR, Brazil
| | - André Armani
- Department of Surgery, Universidade Estadual de Londrina, Londrina, PR, Brazil
| | - Alessandra Lourenço Cecchini
- Laboratory of Molecular Pathology, Universidade Estadual de Londrina, Celso Garcia Cid, PR445, Km 380 University Campus, Londrina, Paraná, CEP 86057-970, Brazil.
| |
Collapse
|
4
|
Riley A, Jones H, England J, Kuvshinov D, Green V, Greenman J. Identification of soluble tissue-derived biomarkers from human thyroid tissue explants maintained on a microfluidic device. Oncol Lett 2021; 22:780. [PMID: 34594421 DOI: 10.3892/ol.2021.13041] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2021] [Accepted: 06/09/2021] [Indexed: 01/08/2023] Open
Abstract
Although a large cohort of potential biomarkers for thyroid cancer aggressiveness have been tested in various formats in recent years, to the best of our knowledge, thyroglobulin and calcitonin remain the only two established biomarkers associated with thyroid cancer management. Our group has recently validated a novel means of maintaining live, human ex vivo thyroid tissue within a tissue-on-chip format. The present pilot study aimed to interrogate the tissue effluent, containing all the soluble markers released by the tissue samples maintained within the devices' tissue chamber, for the presence of markers potentially associated with thyroid cancer aggressiveness. Culture effluent from tissue samples harvested from 19 individual patients who had undergone thyroidectomy for the treatment of suspected thyroid cancer was assessed, first using a proteome profiler™ angiogenesis array kit. Patients were subcategorised as 'aggressive' if they possessed a minimum of N1b level metastases, whilst 'non-aggressive' samples were T3 or lower without evidence of multifocality; and contralateral healthy thyroid tissue was harvested for comparative studies. Levels of Serpin-F1, vascular endothelial growth factor, Thrombospondin-1 and chemokine (C-C motif) ligand were significantly altered and, thus, were further investigated using ELISA to allow for quantitative analysis. The concentration of serpin-F1 was significantly increased in the effluent of aggressive thyroid cancer tissue when compared with levels released by both non-aggressive and benign samples. The present study demonstrated the usability of microfluidic technology for the analysis of the ex vivo tissue secretome in order to identify novel biomarkers.
Collapse
Affiliation(s)
- Andrew Riley
- Faculty of Health Sciences, University of Hull, Hull HU6 7RX, UK
| | - Heidi Jones
- Department of ENT, Hull University Teaching Hospitals NHS Trust, Castle Hill Hospital, Hull HU16 5JQ, UK
| | - James England
- Department of ENT, Hull University Teaching Hospitals NHS Trust, Castle Hill Hospital, Hull HU16 5JQ, UK
| | - Dmitriy Kuvshinov
- Faculty of Engineering, University of Hull, Cottingham Road, Hull HU6 7RX, UK
| | - Victoria Green
- Faculty of Health Sciences, University of Hull, Hull HU6 7RX, UK
| | - John Greenman
- Faculty of Health Sciences, University of Hull, Hull HU6 7RX, UK
| |
Collapse
|
5
|
Goulet CR, Pouliot F. TGFβ Signaling in the Tumor Microenvironment. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2021; 1270:89-105. [PMID: 33123995 DOI: 10.1007/978-3-030-47189-7_6] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Transforming growth factor beta (TGFβ) is a pleiotropic growth factor. Under normal physiological conditions, TGFβ maintains homeostasis in mammalian tissues by restraining the growth of cells and stimulating apoptosis. However, the role of TGFβ signaling in the carcinogenesis is complex. TGFβ acts as a tumor suppressor in the early stages of disease and as a tumor promoter in its later stages where cancer cells have been relieved from TGFβ growth controls. Overproduction of TGFβ by cancer cells lead to a local fibrotic and immune-suppressive microenvironment that fosters tumor growth and correlates with invasive and metastatic behavior of the cancer cells. Here, we present an overview of the complex biology of the TGFβ family, and we discuss the roles of TGFβ signaling in carcinogenesis and how this knowledge is being leveraged to develop TGFβ inhibition therapies against the tumor.
Collapse
Affiliation(s)
- Cassandra Ringuette Goulet
- Oncology Division, CHU de Québec Research Center, Quebec, QC, Canada
- Department of Surgery, Faculty of Medicine, Laval University, Quebec, QC, Canada
| | - Frédéric Pouliot
- Oncology Division, CHU de Québec Research Center, Quebec, QC, Canada.
- Department of Surgery, Faculty of Medicine, Laval University, Quebec, QC, Canada.
- Department of surgery, CHU de Québec Research Center - Laval University, Quebec City, QC, Canada.
| |
Collapse
|
6
|
Long Noncoding RNA CTC Inhibits Proliferation and Invasion by Targeting miR-146 to Regulate KIT in Papillary Thyroid Carcinoma. Sci Rep 2020; 10:4616. [PMID: 32165673 PMCID: PMC7067803 DOI: 10.1038/s41598-020-61577-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2019] [Accepted: 02/26/2020] [Indexed: 12/03/2022] Open
Abstract
Several lines of evidence have shown that long non-coding RNAs (lncRNAs) are dysregulated in many diseases. Nevertheless, the biological relevance of the lncRNAs in papillary thyroid carcinoma (PTC) has not been fully explored. We demonstrated that CTC was a negative regulator of PTC cell migration and invasion in vitro and in vivo. We found that microRNA-146 (miR-146) is an inhibitory target of CTC. We then demonstrated that CTC functioned as a miR-146 decoy to de-repress expression of KIT. Further study demonstrated that CTC modulated the progression and chemoresistance of PTC cells via miR-146 and KIT. The analysis of hundreds of clinical specimens revealed that CTC and KIT levels were downregulated, whereas miR-146 levels were greater in PTC tissues than in normal thyroid. Their expression levels correlated with one another. In conclusion, CTC functions as a competing endogenous RNA to inhibit the progression and chemoresistance of PTC cells, and identifies CTC serve as a potential therapeutic agent to suppress PTC progression.
Collapse
|
7
|
Li G, Kong Q. LncRNA LINC00460 promotes the papillary thyroid cancer progression by regulating the LINC00460/miR-485-5p/Raf1 axis. Biol Res 2019; 52:61. [PMID: 31870440 PMCID: PMC6929379 DOI: 10.1186/s40659-019-0269-9] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2019] [Accepted: 12/09/2019] [Indexed: 02/06/2023] Open
Abstract
Background Papillary thyroid cancer (PTC) is the most common malignancy of all thyroid cancers. LncRNA LINC00460 has been proved to play roles in the oncogenesis and progression of various tumors, including papillary thyroid cancer. However, the potential molecular mechanism of LINC00460 in PTC is poorly investigated. Results LINC00460 was upregulated in PTC tissues and cells. Raf1 was upregulated in PTC tissues, but miR-485-5p was down-regulated. High LINC00460 expression was associated with poor prognosis. LINC00460 knockdown suppressed proliferation, migration, invation and EMT of PTC cells. Bioinformatics prediction revealed that LINC00460 had binding sites with miR-485-5p, which was validated by luciferase reporter assay. In addition, miR-485-5p was confirmed to directly target Raf1 3′-UTR. Moreover, LINC00460 promoted PTC progression by sponging miR-485-5p to elevate the expression of Raf1. Knockdown of LINC00460 restrained tumor growth in vivo. Conclusion LINC00460 induced proliferation, migration, invation and EMT of PTC cells by regulating the LINC00460/miR-485-5p/Raf1 axis, which indicated that LINC00460 may be a potential biomarker and therapeutic target for PTC.
Collapse
Affiliation(s)
- Guangjun Li
- Department of Oncology, Yuncheng County Hospital of Traditional Chinese Medicine, Heze, 274700, Shandong, China
| | - Qingli Kong
- Department of Oncology, The Affiliated Hospital of Jining Medical University, No. 89, Gutun Road, Jining, 272029, Shandong, China.
| |
Collapse
|